What is Xeljanz 5 mg and How Does It Work?

Xeljanz 5 mg contains the active ingredient tofacitinib, which belongs to a class of medications known as JAK inhibitors. Unlike injectable biologics that target external inflammatory proteins, Xeljanz works inside cells by blocking specific enzymes called Janus kinases (JAKs) that play a critical role in the inflammatory process.

When taken twice daily, Xeljanz 5 mg interrupts the signaling pathway that leads to inflammation and immune system overactivity in conditions like rheumatoid arthritis. By inhibiting these JAK enzymes, the medication helps reduce joint pain, swelling, and can slow the progression of joint damage in patients who haven't responded adequately to other treatments like methotrexate.

Medical Conditions Treated with Xeljanz 5 mg

Xeljanz 5 mg has received FDA approval for treating several autoimmune conditions. Its primary indication is for adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In this capacity, it can be used as monotherapy or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).

Beyond rheumatoid arthritis, Xeljanz 5 mg is also approved for treating active psoriatic arthritis in adult patients who have had an inadequate response or intolerance to methotrexate or other DMARDs. Additionally, it's used for treating moderately to severely active ulcerative colitis in adults who have had an inadequate response or intolerance to TNF blockers. For ulcerative colitis, patients typically start with a higher induction dose before moving to the maintenance dose of 5 mg twice daily.

Xeljanz 5 mg Compared to Other Treatment Options

When comparing treatment options for autoimmune conditions, Xeljanz 5 mg offers several distinct advantages over other medications. Unlike biologics from manufacturers like AbbVie (makers of Humira) or Amgen (makers of Enbrel), Xeljanz doesn't require injections or infusions, as it comes in a convenient oral tablet form.

Xeljanz, manufactured by Pfizer, competes with other JAK inhibitors such as Rinvoq from AbbVie and Olumiant from Eli Lilly. Each of these medications works slightly differently and has varying approval indications. While Xeljanz was the first JAK inhibitor approved for rheumatoid arthritis, newer options might offer once-daily dosing compared to Xeljanz's twice-daily requirement for the 5 mg formulation. However, Xeljanz has the advantage of longer-term safety data since it has been on the market longer.

Benefits and Potential Side Effects

The benefits of Xeljanz 5 mg include rapid onset of action, with some patients reporting improvements in symptoms within days to weeks of starting treatment. Clinical trials demonstrated significant improvements in joint pain, swelling, and physical function. The oral administration route eliminates the need for injections, which many patients prefer over biologic medications from companies like Janssen or Novartis.

However, Xeljanz 5 mg comes with important safety considerations. The FDA has issued boxed warnings about increased risks of serious infections, malignancy, major adverse cardiovascular events, thrombosis, and mortality. Common side effects include upper respiratory tract infections, headache, diarrhea, and nasopharyngitis. Less common but serious side effects include herpes zoster (shingles), opportunistic infections, and abnormal laboratory values (including changes in cholesterol levels and decreased blood cell counts). Regular monitoring through laboratory tests is essential while taking this medication. Patients with a history of blood clots, heart disease, or cancer should discuss these risks carefully with their healthcare provider before starting Xeljanz.

Cost and Insurance Coverage for Xeljanz 5 mg

The cost of Xeljanz 5 mg can be substantial without insurance coverage. The manufacturer, Pfizer, offers patient assistance programs through their Pfizer RxPathways program for eligible patients who need help affording their medication. This program can provide co-pay assistance cards that may reduce out-of-pocket costs significantly for commercially insured patients.

Most insurance plans and Medicare Part D cover Xeljanz, but they typically require prior authorization and may place it on a specialty tier with higher co-pays. Many plans require patients to try and fail other treatments like methotrexate before approving Xeljanz. Patients should check with their insurance provider about specific coverage details and potential out-of-pocket costs. Some patients may also explore options through specialty pharmacies like CVS Specialty or Accredo, which might offer additional support services for patients on specialty medications.

Conclusion

Xeljanz 5 mg represents an important advancement in the treatment of autoimmune conditions like rheumatoid arthritis, offering an oral alternative to injectable biologics. While it provides significant benefits in terms of convenience and efficacy, patients must carefully weigh these against potential risks and work closely with healthcare providers to monitor for side effects. With proper medical supervision and adherence to safety monitoring, Xeljanz 5 mg can be an effective component of a comprehensive treatment plan for those struggling with inflammatory conditions. For those concerned about affordability, exploring patient assistance programs through Pfizer may help make this treatment more accessible.

Citations

This content was written by AI and reviewed by a human for quality and compliance.